Novartis VAY736: A subject, investigator, and sponsor blinded randomized placebo controlled multicenter study to investigate VAY736 in patients with idiopathic pulmonary fibrosis
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
June 19, 2018
End Date
November 16, 2023
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
June 19, 2018
End Date
November 16, 2023